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ABSTRACT
Background: While interleukin-18 (IL-18) plays an important role in the innate and adaptive immune re-
sponses, it can also cause severe allergic inflammatory reactions. Thus it is a molecule currently being targeted
for therapy. The natural intrinsic inhibitor of IL-18 receptor activation, IL-18 binding protein (IL-18BP), shows a
great potential for the treatment of allergy.
Methods: Expression and purification of recombinant human IL-18BP (rhIL-18BP) were performed using the
baculovirus system to develop a therapeutic molecule for the treatment of IL-18-related diseases and to investi-
gate the structural basis of its inhibitory mechanism.
Results: Purified rhIL-18BP potently inhibited the production of interferon-gamma by peripheral blood mono-
nuclear cells in the presence of lipopolysaccharide and by human myelomonocytic KG-1 cells in the presence
of IL-18 (IC50 = 0.4 nM). Surface plasmon resonance showed a high affinity (Kd = 0.46 nM) for rhIL-18BP in
binding hIL-18. Structural analysis indicated that the stoichiometry between IL-18 and IL-18BP is 1 : 1 in solu-
tion and the model structure of the complex suggests that the key residues on IL-18 (L5, K53, S55) and the es-
timated key residues on IL-18BP (F93,Y97, F104) could have interactions. The structural mechanism of IL-
18BP inhibition might be a competition for Site 2 on rIL-18 so that IL-18BP can prevent IL-18 receptor alpha
from binding to Site 2 and inhibit IL-18 receptor activation.
Conclusions: IL-18BP has unique features with respect to its structure, binding mode and inhibitory mecha-
nism. It is a molecule that has a great potential for the therapy of allergy.
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INTRODUCTION
Interleukin-18 (IL-18) is a cytokine originally found to
induce the production of interferon-gamma (IFN-γ) in
T lymphocytes, and plays an important role in innate
and adaptive immune systems.1,2 To initiate the IL-18
pathway, the IL-18 receptor needs to be activated,
which requires IL-18 receptor alpha (IL-18Rα, for-
merly known as IL-1Rrp) and IL-18 receptor beta (IL-
18Rβ, formerly known as IL-1RAcPL) to heterodimer-
ize.2
The structure of human IL-18 has been determined
and it has shown that hIL-18 contains the β-trefoil fold
that is similar to those found in interleukin-1 (IL-1)
family members, making a new structural family in
the interleukins.3,4 Also, using mutant recombinant
human IL-18 (rhIL-18) proteins in receptor-binding
and cellular response assays, three important binding
sites have been identified.3 Two of these sites are im-
portant for binding to IL-18Rα, and the third is in-
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volved in cellular responses but not in IL-18Rα bind-
ing.3
By comparing the structure and the receptor bind-
ing sites of IL-18 with those of the IL-1 family mem-
bers, a two-step ternary complex formation that in-
volves IL-18, IL-18Rα, and IL-18Rβ has been re-
vealed.4 The formation of the ternary complex can
then trigger a signal cascade that activates IL-1 recep-
tor activating kinase (IRAK), tumor necrosis factor
(TNF)-receptor associated factor 6 (TRAF6) and nu-
clear factor-kappa B (NF-κB).5,6
In medicine, the aberrant expression of IL-18 has
been suggested to be responsible for several inflam-
matory conditions, such as allergies, autoimmune dis-
eases, and neurological disorders.2,7 Serum concen-
trations of IL-18 and IgE have been correlated with
disease severity in atopic dermatitis (AD) patients.7-9
In these patients, the serum concentration of IL-18 is
significantly higher than that found in healthy indi-
viduals.9 Furthermore, in response to lipopolysaccha-
ride (LPS), leukocytes prepared from the peripheral
blood of AD patients produced more IL-18 than the
cells of healthy individuals.7,8 In patients with bron-
chial asthma, the level of serum IL-18 is also elevated,
and seems to correlate with disease severity.7,10-14 As
well, polymorphic genes for IL-18 and IL-18Rα have
been found in association with allergy.15-17 Collec-
tively, these studies strongly suggest that IL-18 is re-
sponsible for causing andor maintaining inflamma-
tory conditions. Thus, IL-18 may be an ideal therapeu-
tic target for the treatment of allergy.7
In clinical settings, humanized antibodies are
widely used as therapeutic agents for the treatment of
many diseases, including allergy.18 Although anti-IL-
18 antibody has been proven to be effective for pre-
venting liver damage in mice, to date, there are no
specific inhibitors against IL-18 to treat patients.1,7,18
To this end, Hamasaki et al. recently reported a hu-
man anti-hIL-18 antibody (h18―108) that is capable of
inhibiting IFN-γ production in a cell line.19
For therapeutic purposes, IL-18 binding protein
(IL-18BP), a natural intrinsic inhibitor of hIL-18, may
be an ideal candidate for use as a therapeutic agent.20
One reason is that it is a natural inhibitor of IL-18,
and its functional homologs have also been found in
poxviruses, which utilize proteins to evade the im-
mune system.21-26 Also, the severity of autoimmune
diseases appears to be influenced by the relative lev-
els of IL-18 and IL-18BP.27 Furthermore, IL-18BP has
been shown to prevent disease development in vari-
ous mouse models, which strongly supports IL-
18BP’s potential as a therapeutic agent.28-30
In this study, we performed high expression and
purification of recombinant human IL-18BP (rhIL-
18BP) using the baculovirus system to develop a
therapeutic molecule for the treatment of IL-18-
related diseases. A structural analysis of rhIL-18BP
was performed to investigate the structural basis of
its inhibitory mechanism.
METHODS
CONSTRUCTION OF EXPRESSION VECTOR
FOR hIL-18BP
The IL-18BP isoform-a was selected from six iso-
forms of IL-18BP, because isoform-a most strongly in-
hibits IL-18 activity on human peripheral blood mono-
nuclear cells (PBMCs) or human cell lines and has
been widely used as the representative of the iso-
forms.31,32 Total mRNA was extracted from the blood
of a healthy volunteer, and single-stranded cDNAs
were synthesized at 72℃ for 60 minutes using re-
verse transcriptase and oligo-dT primers. Only the
coding region of the mature hIL-18BP isoform a
(NM173042, residues 27―193 aa,) was amplified by
PCR. The amplified fragment was cloned into T-
vector (Invitrogen, USA), because the amino acid
residues 1 to 26 of the hIL-18BP are recognized as a
signal peptide in mammalian cells (Fig. 1A). One of
the primers used in the PCR contained an EcoRI site
and a signal peptide sequence for Sf9 insect cells, and
by design, these were placed immediately upstream
of the first codon of the mature hIL-18BP. The sec-
ond primer contained the His-6 tag sequence, a stop
codon, and a NotI site. The purified PCR product was
subcloned into the pFastBac1 vector (Invitrogen,
USA). The DNA sequence of the clone was con-
firmed by bi-directional sequencing. The construct
was called pFastBac1-hIL-18BP-His6 (Fig. 1B).
PRODUCTION OF RECOMBINANT BACULOVI-
RUS
Generation of recombinant baculovirus expressing
hIL-18BP in Sf9 cells was carried out with a Bac-to-
Bac baculovirus expression kit (Invitrogen, USA). In
accord with the manufacturer’s protocol, pFastBac1-
hIL-18BP-His6 was introduced into E.coli DH10Bac
(Invitrogen, USA) for the transposition of IL-18BP
into baculovirus genomic DNA (bacmid). Colonies
containing the recombinant bacmid were isolated us-
ing a miniprep plasmid isolation kit (Promega, USA).
The recombinant bacmid DNA was then used to
transfect Sf9 cells, which were plated at a density of
1 × 106 cells per 35-mm well and then transfected with
the bacmid DNA using Cellfectin reagent (Invitrogen,
USA). The recombinant virus was harvested 72 hours
post-transfection. Plaque assays were performed with
the supernatants to determine the titer of recovered
virion particles. Plaque assay and propagation of vi-
ruses were carried out according to the manual pro-
vided with the kit.
INSECT CELL CULTURE
Sf9 insect cells were cultured and routinely sub-
cultured at 27℃. They were maintained either as a
monolayer or as a suspension culture in Sf-900 II
SFM (Invitrogen, USA) without antibiotics. Insect
Structural Analysis of IL-18BP
Allergology International Vol 57, No4, 2008 www.jsaweb.jp 369
Fi
g.
 1
 
E
xp
re
ss
io
n 
an
d 
pu
rif
ic
at
io
n 
of
 rh
IL
-1
8B
P
. A
, A
lig
nm
en
t f
or
 IL
-1
8B
P
s.
 T
he
 s
ig
na
l p
ep
tid
e 
re
si
du
es
 o
f t
he
 h
IL
-1
8B
P
 in
 m
am
m
al
ia
n 
ce
lls
 a
re
 b
ox
ed
. 
E
st
im
at
ed
 k
ey
 re
si
du
es
 o
n 
hI
L-
18
B
P
 fo
r h
IL
-1
8 
bi
nd
in
g 
ar
e 
hi
gh
lig
ht
ed
 in
 y
el
lo
w
.26
 B
, A
 m
ap
 o
f t
he
 c
on
st
ru
ct
 u
se
d 
fo
r e
xp
re
ss
io
n 
of
 h
IL
-1
8B
P
 in
 th
e 
ba
-
cu
lo
vi
ru
s 
sy
st
em
. C
, P
ur
ifi
ca
tio
n 
of
 r
hI
L-
18
B
P
. L
an
e 
1:
 m
ed
iu
m
, l
an
e 
2:
 D
E
A
E
, l
an
e 
3:
 N
iN
TA
, l
an
e 
4:
 G
el
 fi
ltr
at
io
n.
 D
, D
eg
ly
co
sy
la
tio
n 
by
 tr
ifl
uo
ro
m
et
h-
an
e 
su
lfo
ni
c 
ac
id
. L
an
e 
1:
 b
ef
or
e 
de
gl
yc
os
yl
at
io
n,
 la
ne
 2
: a
fte
r d
eg
ly
co
sy
la
tio
n.
A
B
C
D
M
W
1
2
50 30 20
50 30 20
M
W
1
2
3
4
1
1
0
2
0
3
0
4
0
5
0
H
U
M
A
N
M
T
M
R
H
N
W
-
T
P
D
L
S
P
L
W
V
L
L
L
C
A
H
V
V
T
L
L
V
R
A
T
P
V
S
Q
T
T
T
A
A
T
A
S
V
R
S
T
K
D
C
H
IM
P
A
N
Z
E
E
M
T
M
R
H
N
W
-
T
P
D
L
S
P
L
W
V
L
L
L
C
A
H
V
V
T
L
L
V
R
A
T
P
V
S
Q
T
T
K
A
A
T
A
S
V
R
S
T
K
D
M
O
U
S
E
M
T
M
R
H
C
W
-
T
A
G
P
S
S
W
W
V
L
L
L
Y
V
H
V
I
-
-
L
A
R
A
T
S
A
P
Q
T
T
-
-
A
T
V
L
T
G
S
S
K
D
R
A
T
-
-
M
R
H
C
G
C
A
A
D
P
S
P
W
W
V
L
L
L
Y
V
H
V
V
-
I
L
A
R
A
T
S
A
P
L
T
T
-
-
A
T
V
L
T
R
S
S
K
D
D
O
G
-
-
M
R
Q
N
W
-
T
P
D
P
S
P
L
R
V
L
L
L
C
V
H
M
F
C
H
L
A
G
A
T
P
V
H
Q
A
T
-
-
A
A
A
S
A
A
I
P
K
D
6
0
7
0
8
0
9
0
1
0
0
H
U
M
A
N
P
C
P
S
Q
P
P
V
F
P
A
A
K
Q
C
P
A
L
E
V
T
W
P
E
V
E
V
P
L
N
G
T
L
S
L
S
C
V
A
C
S
R
F
P
N
F
S
I
L
Y
C
H
IM
P
A
N
Z
E
E
P
C
P
S
Q
P
P
V
F
P
A
A
K
Q
C
P
A
L
E
V
T
W
P
E
V
E
V
P
L
N
G
T
L
S
L
S
C
V
A
C
S
R
F
P
N
F
S
I
L
Y
M
O
U
S
E
P
C
S
S
W
S
P
A
V
P
T
-
K
Q
Y
P
A
L
D
V
I
W
P
E
K
E
V
P
L
N
G
T
L
T
L
S
C
T
A
C
S
R
F
P
Y
F
S
I
L
Y
R
A
T
P
C
S
S
W
S
P
A
V
P
T
K
Q
Y
P
T
L
D
V
I
W
P
E
K
E
V
P
L
N
G
T
L
T
L
S
C
T
A
C
S
R
F
P
N
F
S
I
L
Y
D
O
G
S
C
L
S
W
-
-
L
L
T
A
K
Q
C
P
A
L
E
V
A
G
P
E
V
E
V
P
L
N
G
M
L
T
L
S
C
T
A
C
S
R
S
P
-
F
N
I
L
F
1
1
0
1
2
0
1
3
0
1
4
0
1
5
0
H
U
M
A
N
W
L
G
N
G
S
F
I
E
H
L
P
G
R
L
W
E
G
S
T
S
R
E
R
G
S
T
G
T
Q
L
C
K
A
L
V
L
E
Q
L
T
P
A
L
H
S
T
N
F
S
C
H
IM
P
A
N
Z
E
E
W
L
G
N
G
S
F
I
E
H
L
P
G
Q
L
W
E
G
S
T
S
R
E
R
G
S
T
G
T
Q
L
C
K
A
L
V
L
E
Q
L
T
P
A
L
H
S
T
N
F
S
M
O
U
S
E
W
L
G
N
G
S
F
I
E
H
L
P
G
R
L
K
E
G
H
T
S
R
E
H
R
N
T
S
T
W
L
H
R
A
L
V
L
E
E
L
S
P
T
L
R
S
T
N
F
S
R
A
T
W
L
G
N
G
S
F
I
E
H
L
P
G
R
L
R
E
G
H
T
S
R
E
Q
R
N
A
S
T
W
L
H
R
A
L
V
L
E
E
L
S
P
S
L
L
S
T
N
F
S
D
O
G
W
M
G
N
G
S
F
I
E
H
L
P
G
R
L
R
E
G
S
T
S
R
E
S
R
G
E
H
T
Q
L
R
R
T
L
V
L
E
E
L
S
P
T
L
R
N
T
D
F
S
1
6
0
1
7
0
1
8
0
1
9
0
H
U
M
A
N
C
V
L
V
D
P
E
Q
V
V
Q
R
H
V
V
L
A
Q
L
W
A
G
L
R
A
T
L
P
P
T
Q
E
A
L
P
S
S
H
S
S
-
P
Q
Q
Q
G
C
H
IM
P
A
N
Z
E
E
C
V
L
V
D
P
E
Q
V
V
Q
R
H
V
V
L
A
Q
L
W
A
G
L
R
A
T
L
P
P
T
Q
E
A
L
P
S
S
H
S
S
-
P
Q
Q
Q
G
M
O
U
S
E
C
L
F
V
D
P
G
Q
V
A
Q
Y
H
I
I
L
A
Q
L
W
D
G
L
K
T
A
P
S
P
S
Q
E
T
L
-
S
S
H
S
P
V
S
R
S
A
G
P
G
V
A
R
A
T
C
L
F
V
D
P
G
Q
V
A
Q
Y
H
V
I
L
A
Q
L
W
D
G
L
K
T
A
P
S
P
S
Q
E
T
L
-
S
S
H
S
P
G
P
R
S
A
G
P
G
A
P
D
O
G
C
V
F
A
D
P
S
H
T
T
Q
Q
H
V
V
L
A
Q
L
W
A
G
L
E
T
V
A
P
S
T
Q
E
A
-
P
P
S
S
S
P
L
S
R
L
I
T
T
E
K
F
cells in a monolayer culture were plated at a density
of 1.0 × 106 cellswell in six-well plates. These cells
were used to transfect recombinant bacmid DNA or
for the determination of the optimal multiplicity of in-
fection (MOI). The cells in the suspension culture
were grown in a 25 ml volume of Sf-900 II SFM using
125 ml disposable Erlenmeyer flasks (Nalgene, USA).
The flasks were maintained in a Bioshaker BR40LF
(TAITEC, Japan) and were subjected to rotary shak-
ing at a speed of 95 rpm (amplitude 35 mm). Stock
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Sf9 cells that were grown in suspension were seeded
at 0.5 × 106 cellsml and culture passage was per-
formed every 3 days during the log phase (4―6 × 106
cellsml).
PURIFICATION OF hIL-18BP FROM BACULO-
VIRUS-INFECTED SF9 CELL CULTURE MEDIUM
For the purification of rhIL-18BP, Sf9 cells were sub-
cultured in 1 L Fernbach flasks. Each flask received
400 ml of the cell culture at a concentration of 0.5 ×
106 cellsml. Shaking speed was set to 71 rpm (Am-
plitude 50 mm). When the subcultured cells reached
a concentration of 2.0 × 106 cellsml, Sf9 cells were in-
fected with the recombinant baculovirus at an MOI of
0.1 plaque-forming units (pfu) per ml and were incu-
bated for up to 72 hours.
Secreted rhIL-18BP was processed by centrifuga-
tion and filtration. Then, the medium was applied to a
DEAE-Sepharose (GE health care, Sweden) open col-
umn (Bio-Rad, USA) equilibrated with buffer A (50
mM sodium-phosphate, pH 6.0 containing 50 mM
NaCl). The flow through was concentrated 10-fold us-
ing a tangential flow filtration system; Masterflex LS
(Barnant Company, USA) and viva flow 50 (Vivas-
ciece AG, Germany). This was then dialyzed against
buffer B (50 mM Sodium Phosphate, 0.5 M NaCl, 10
mM Imidazol, pH 7.4) and insoluble material re-
moved by centrifugation at 2 × 104 g; himac CR 20B2
(Hitachi, Japan). Dialyzed sample was loaded onto a
Ni-agarose (GE Healthcare, Sweden) column equili-
brated with buffer B. The column was then washed
with buffer B and bound proteins were eluted by an
elution buffer B with varying imidazol concentrations
(50, 100, 200, 300 and 500 mM). The eluted fraction
of rhIL-18BP was concentrated and further purified
using a superdex75 1660 (GE Healthcare, Sweden)
size exclusion column equilibrated with 50 mM potas-
sium phosphate buffer pH 7.0, containing 150 mM
KCl and 0.1 mM EDTA. The purity of the preparation
was assessed by SDS-PAGE.
DEGLYCOSYLATION OF rhIL-18BP BY TRIFLU-
OROMETHANE SULFONIC ACID
Deglycosylation was performed in a draft chamber
(DF-19RST, DALTON, Japan). Freeze dried IL-18BP
(30 μg) in glass vial and trifluoromethane sulfonic
acid (TFMS) (Sigma Aldrich, Japan) was chilled on
ice prior to mixing. Fifty micro liters of TFMS was
added in a glass vial and gently mixed. The vial was
then incubated for 50 hours on ice and neutralized
with a solution of 500 μl of 1M-Tris. Neutralized rhIL-
18BP was concentrated with a MicroconYM-10 (Milli-
pore, USA) and dialyzed against 20 mM sodium phos-
phate buffer of pH 7.0 containing 150 mM NaCl be-
fore SDS-PAGE.
N-TERMINAL SEQUENCING BY EDMAN DEGRA-
DATION
Purified proteins were electro-blotted onto a polyvi-
nylidene difluoride membrane (Amersham Bi-
osciences, UK) after SDS-PAGE for 1 hour at 200 mA
in solution that contained 25 mM Tris, 192 mM gly-
cine, and 10% methanol. The membrane was briefly
stained with CBB R250 (Wako, Japan) and de-stained
extensively in 45% and 90% methanol containing 7%
acetic acid. The amino acid sequence analysis of the
recombinant protein was carried out by an Edman
degradation technique using a pulse liquid automatic
sequencer (Model 491HT, Applied Biosystems,
USA).
FUNCTIONAL ANALYSIS OF rhIL-18BP
Biological activity of rhIL-18BP was assayed by meas-
uring its ability to inhibit the production of IFN-γ.
This was performed as previously described with mi-
nor modifications.17 Briefly, PBMCs were isolated
from three volunteers and suspended at 1 × 106 ml
in the culture medium. PBMCs were cultured in the
presence or absence of 1 ngml of the LPS with or
without rhIL-18BP (400 ngml) for 24 hours at 37℃
in a humidified atmosphere containing 5% CO2. The
cell culture supernatants were collected in test tubes,
and the samples were spun to get rid of cells and then
stored at −80℃ until assay. The concentration of
IFN-γ was measured by enzyme-linked immunosorb-
ent assay (ELISA), as previously described.32
MEASUREMENT OF rhIL-18BP-MEDIATED INHI-
BITION OF IFN-γ PRODUCTION IN KG-1 CELLS
In hIL-18 inhibition assay, the level of inhibition is de-
termined by the amount of IFN-γ produced by the tar-
get cells. A detailed description has been reported.32
Briefly, human myelomonocytic KG-1 cells (ATCC
CCL246) were grown in RPMI1640 (Invitrogen, USA)
supplemented with 10% heat-inactivated fetal calf se-
rum (Sigma Aldrich, USA), L-glutamine (2 mmolL)
(Wako, Japan), penicillin (100 Uml) (Meiji, Japan),
and streptomycin (100 μgml) (Meiji, Japan). The
rhIL-18 and rhIL-18BP prepared in our laboratory
were mixed in the RPMI1640 medium noted above.
The concentration of rhIL-18 was 4 ngml and rhIL-
18BP was from 0 to 250 ngml. The mixed samples
were incubated at 37℃ for 1 hour. Then, 100 μl of the
mixture was added to the wells of a 96-well plate
(Nunc, Denmark), which contained 100 μl of KG-1
cells (3 × 106 cellsml) (The final concentration of
rhIL-18 was 2 ngml and rhIL-18BP was from 0 to 125
ngml). The plate was further incubated at 37℃ for
24 hours in 5% CO2. The culture supernatants were
collected, and the amount of IFN-γ produced by KG-1
cells was determined by ELISA.32 IC50, the concen-
tration of antagonists required to inhibit 50% of IFN-γ
production by KG-1 cells stimulated with hIL-18, was
then calculated.
Structural Analysis of IL-18BP
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Fig. 2 Functional activity of purified rhIL-18BP. A, Inhibition of IFN-γ production by rhIL-18BP in LPS-stimu-
lated human PBMCs. The numbers on the horizontal axis show the subject numbers. Open box, control; 
black box, LPS stimulation, grey box, LPS stimulation with rhIL-18BP. B, Inhibition of IFN-γ production by a 
human cel line, KG-1. C, Dose-response of the rIL-18BP/rhIL-18 interaction by surface plasmon resonance 
(Kd＝0.46 nM).
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MEASUREMENT OF rhIL-18BP’S BINDING AC-
TIVITY BY SURFACE PLASMON RESONANCE
EXPERIMENT
In vitro affinity of the hIL-18 for rhIL-18BP was meas-
ured at 25℃ by surface plasmon resonance (SPR) us-
ing a BIAcore3000 (BIAcore, Sweden). A specific
binding surface was prepared by coupling the anti-
penta-His antibody (QIAGEN K.K, Japan) to a CM5
sensor chip by the standard amine coupling method,
as recommended by BIAcore. Then, 6-his tagged
rhIL-18BP was injected over the sensor chip and im-
mobilized. The coupling density was limited to 120
resonance units (RU) . Samples of hIL-18 were di-
luted to varying concentrations ranging from 2 to 32
nM in HBS-EP buffer (10 mM HEPES, pH 7.4, 150
mM NaCl, 3.0 mM EDTA, 0.005% (vv) surfactant
P-20). For dissociation constant analysis, diluted hIL-
18 samples were injected over the sensor chip at a
flow rate of 20 μlmin. The sensor surface was regen-
erated by two 60-second pulses of 0.2 M glycine-HCl,
pH 2.2. The sensorgrams obtained from various con-
centrations of rhIL-18 were fitted with BIAEVALU-
ATION software (BIAcore, Sweden) in a 1-to-1 bind-
ing model.
ANALYTICAL GEL FILTRATION OF rhIL-18BP
The molecular mass of purified rhIL-18BP and the
complex of rhIL-18 and rhIL-18BP were determined
by size exclusion chromatography. A superdex200
1030 GL column (GE Healthcare, Sweden) attached
to a FPLC system (GE Healthcare, Sweden) was util-
ized and the study conducted at 4℃. The column was
equilibrated with 50 mM potassium phosphate buffer
of pH 7.0, containing 150 mM KCl and 0.1 mM
EDTA. The column was calibrated with the following
gel filtration standards (Bio-Rad Laboratories, USA):
thyroglobulin (670 kDa), bovine γ-globulin (158 kDa),
chicken ovalbumin (44 kDa), equine myoglobin (17
kDa), and vitamin B12 (1.35 kDa) at a flow rate of 0.25
mlmin. Samples with only hIL-18BP, only rhIL-18 or
a mixture of rhIL-18BP and rhIL-18 at a 1 : 2 ratio
were used for the analysis. Protein elution was moni-
tored and detected by UV absorption at 280 nm. We
plotted the logarithm of the molecular weight versus
the elution volume, and calculated the correlation
line. The elution volume of rhIL-18BP and the com-
plex of rhIL-18rhIL-18BP were plotted and the de-
duced molecular weight determined.
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Fig. 3 Stoichiometric analysis of the rhIL-18/rhIL-18BP 
complex. A, Gel filtration of rhIL-18BP. B, Gel filtration of the 
rhIL-18BP/rhIL-18 complex. A solid line indicates the sam-
ple that contained a mixture of rhIL-18BP and rhIL-18 at 1 : 2 
ratio, a dashed line, indicates the sample with only rhIL-18.
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HOMOLOGY MODELING OF THE STRUCTURES
The sequence alignment of IL-18BP from different
species was performed using ClustalW (http:www2.
ebi.ac.ukclustalw) with a BLOSUM matrix. Homol-
ogy modeling was performed using MOE software
(CCG, Inc., Canada) with a combination of segment-
matching and modeling of indels.33,34 The templates
used for the modeling were as follows: the NMR
structure of hIL-18 (PDB: 1J0S) and the crystal struc-
ture of the domain 3 of hIL-1Rα (PDB: 1ITB) for the
hIL-18: hIL-18BP complex; the NMR structure of hIL-
18 (PDB: 1J0S) and the crystal structure of the hIL-
10anti-IL-10 Fab complex (PDB: 1LK3) for the hIL-
18human anti-hIL-18 Fab interaction. The modeled
structures were refined by further energy minimiza-
tion.
RESULTS
CHARACTERIZATION OF THE PURIFIED rhIL-
18BP
High expressions of rhIL-18BP were obtained using
the baculovirus expression system. We were able to
obtain a yield of 2.5 mgL of rhIL-18BP after Ni-NTA
column purification (Fig. 1C). A further purification
by gel filtration showed excellent purity and yielded
1.8 mgL (Fig. 1C). To check the purity of the pro-
tein, electrophoresis was performed. Although the
band appeared smeary, when we deglycosylated it
with TFMS, a single sharp band of 18 kDa in size was
detected (Fig. 1D). Edman degradation analysis of
rhIL-18BP revealed the expected five N-terminal
amino acid residues: (LVRAT). The sequence verified
the identity of the expressed protein and indicated
that the signal peptide from the vector was correctly
cleaved at the N-terminal residue of mature rhIL-18
BP.
FUNCTIONAL ACTIVITY OF THE rhIL-18BP
The biological activity of rhIL-18BP was tested by
measuring its ability to inhibit the production of IFN-γ
by LPS-stimulated PBMCs from volunteers (Fig. 2A).
The rhIL-18BP showed distinct inhibitory actions
against IFN-γ production by PBMCs in response to
LPS. rhIL-18BP only partly inhibited IFN-γ production
by PBMCs from volunteer #1, while it almost com-
pletely inhibited those from volunteers #2 and #3
(Fig. 2A) . This diversity might be partly explained by
the different amounts of IL-18 released from PBMCs
of individual volunteers andor in part by the differ-
ent productions of other IFN-γ-related cytokines,
such as IL-12 and IL-15.8,17,35,36 As well, rhIL-18BP in-
hibited the production of IFN-γ by human KG-1 cells
in the presence of IL-18 (IC50 = 0.4 nM, Fig. 2B).
His-tagged rhIL-18BP was immobilized on a
BIAcore sensor chip coated with anti-His-tag antibod-
ies and its binding activity monitored in real time with
a BIAcore 3000 sensor. A sensorgram of rhIL-18
showed a rapid increase in signal during the associa-
tion phase and a slow decline in the dissociation
phase (Fig. 2C), demonstrating a fast on-rate and a
slow off-rate. The estimated Kd of 0.46 nM was simi-
lar to results previously reported, indicating that the
produced rhIL-18BP had proper structural fold-
ing.25,26,31
STRUCTURAL ANALYSIS OF rhIL-18BP
Gel filtration analysis revealed that rhIL-18BP is a
monomer in solution (Fig. 3A) and that a complex of
rhIL-18 and rhIL-18BP could be made in the same
molar ratio (Fig. 3B). Together with the molecular
weight of the complex, it is suggested that the com-
plex could be made by one hIL-18 and one hIL-18BP
(Fig. 3B).
Based on the results of analytical gel filtration, a
model structure of the rhIL-18rhIL-18BP complex
was constructed using the NMR structure of hIL-18
and the crystal structure of the domain 3 of IL-1Rα as
templates3 (Fig. 4). The analysis of the amino acid se-
quence alignment for IL-18BP revealed that the resi-
dues that are involved in the binding of hIL-18 are
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Fig. 4 A structural model of the hIL-18/hIL-18BP complex. A, Surface of hIL-18. 
Functional binding residues on hIL-18 for hIL-18BP are colored in orange. B, A struc-
tural model of the rhIL-18BP monomer. Estimated functional key residues of hIL-18BP 
for hIL-18 are shown as atoms in red. C, A model of the hIL-18/hIL-18BP complex (hIL-
18 as a ribbon model, hIL-18BP as a surface representation, colored as in A or B).
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Fig. 5 Human IL-18 interacts diferently with diferent proteins through its three binding sites. A, Recep-
tor binding sites on hIL-18.3 Sites 1, 2 and 3 are indicated in red, orange, and blue, respectively. B, C, D, 
Models of complexes between hIL-18 and hIL-18Rα (in grey), hIL-18BP (in yelow) and human Anti-hIL-
18 Fab (in yelow).
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Fig. 6 A schematic model of IL-18 receptor activation and inhibition. A two-step complex forma-
tion model of IL-18 signaling is shown at the top. The inhibitory mode of IL-18BP or Fab fragment 
of h18―108 is shown at the botom. Sites 1, 2 and 3 of hIL-18 are indicated in red, orange, and 
blue, respectively.
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highly conserved between species25,26 (Fig. 1A). Our
model showed that the three key residues (F93, Y97,
and F104) that are involved in binding IL-18 make hy-
drophobic patches that align with the binding inter-
faces of hIL-18 (Fig. 4C). The three key residues of
hIL-18 for binding (L5, K53, and S55) have been
shown to be involved in the interaction with hIL-
18BP.26
DISCUSSION
Our previous structural analysis of the IL-18IL-18 re-
ceptor interaction showed that there are 3 distinct
and important binding sites on the surface of IL-18
(Fig. 5A).3 Two of the sites (Sites 1 and 2) are respon-
sible for binding to IL-18Rα while the third site is in-
volved in binding to IL-18Rβ (Fig. 5A，B). Site 2 resi-
due is also important for IL-18BP binding3 (Fig. 5A，
C). A recent study showed that a single-chain Fv
(scFv) of an anti-human IL-18 antibody binds to Site 3
of IL-18 (Fig. 5A，D).19 scFv (h18―108) showed a
moderate binding affinity (Kd = 50 nM), whereas the
Fab fragment of h18―108 showed a higher affinity
(Kd = 3.7nM), suggesting that the stability of the
binding surface structure could improve the affinity.19
Further, hIL-18BP, which has a smaller molecular
mass than scFv, showed a greater than 100-fold
higher affinity (Kd = 0.46 nM)25,26,31 than scFV. This
suggested that the evolutionally improved structure
of IL-18BP provided an optimal biding surface com-
plementarity. Based on this, perhaps one could opti-
mize the binding affinity of h18―108 by modifying the
surface structure through in vitro mutagenesis or
through a computational design, as it has been dem-
onstrated for the anti-epidermal growth factor recep-
tor drug, Cetuximab.37
IL-18 activates IL-18 receptor through a two-step
binding mechanism as shown3 in Figure 6. According
to this model, the inhibitory mechanisms of IL-18BP
and the Fab fragment of h18―108 antibody are differ-
ent (Fig. 6). IL-18BP inhibits the receptor activation
by competing for Site 2 on IL-18, which is also a bind-
ing site for IL-18Rα. On the other hand, the Fab frag-
ment of h18―108 antibody binds to Site 3 on IL-18 to
block IL-18 from binding to IL-18Rβ3 (Fig. 6). The
IC50 of IL-18BP has been shown to fall in the range of
0.04―0.46 nM, while it is 100 nM for the Fab frag-
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ment.19 This huge difference in IC50 may reflect the
type of inhibitory mechanism that is employed (Fig.
6). Interestingly, an intact form of h18―108 antibody,
an IgG molecule, has a much higher affinity with a
Kd of 0.64 nM and an IC50 of 5 nM.19 This improve-
ment is most likely the result of its overall stability
and the bivalency of the intact antibody molecule. Re-
gardless of the affinity, these different molecules will
be useful for determining the precise mechanism by
which IL-18 receptor is activated or inhibited. Infor-
mation gained from such studies will undoubtedly
help us design potent therapeutic reagents.
A number of drugs targeting and neutralizing the
deleterious effects of cytokines have been developed.
Etanercept is a soluble fusion protein that is com-
posed of two tumor necrosis factor alpha (TNF-α) re-
ceptors (p75) and a Fc fragment of a human IgG1
molecule; it has been shown to be effective and safe
in patients with rheumatoid arthritis.38 Recently, it
was reported that the blockade of TNF-α by etaner-
cept had efficacy in patients with asthma.39,40 In addi-
tion to the anti-TNF drugs, the role of IL-18 in allergy
suggests that drugs that neutralize the effect of IL-18,
such as monoclonal antibodies or IL-18BP, may also
be useful for the management of allergy.7 The chemi-
cal characteristics of IL-18BP (a single polypeptide, a
monomer, and with a low molecular weight of 25
kDa) support its use in clinical settings. Because of
these characteristics, it is possible that its dosage
could be lower than that of molecules, such as mono-
clonal antibodies and etanercept (multiple polypep-
tides, oligomer, high molecular weight of > 300 kDa)
that are much bigger and more complex. Establish-
ing a system that enables researchers to highly ex-
press the desired protein to study its structural
mechanism could open avenues of research to de-
velop new reagents and strategies for the treatment
of various diseases, including allergy.
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